The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The impact of body mass index on survival in stage 3 and 4 lung cancer.
Kit Man Wong
No relevant relationships to disclose
Sinead Cuffe
No relevant relationships to disclose
Linda E. Coate
No relevant relationships to disclose
Osvaldo Espin-Garcia
No relevant relationships to disclose
Kevin Boyd
No relevant relationships to disclose
Ronald Feld
No relevant relationships to disclose
Natasha B. Leighl
No relevant relationships to disclose
Frances A. Shepherd
Consultant or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck; Recombio; Roche
Stock Ownership - Lilly; Pfizer
Honoraria - GlaxoSmithKline; Lilly; Roche
Expert Testimony - AstraZeneca
Wei Xu
No relevant relationships to disclose
Geoffrey Liu
No relevant relationships to disclose